Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4337713 in FAP-Positive Solid Tumors (FiREBOLT)
NCT07213791Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Jul 2028
- Modality
- Peptides, Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of PNT6555 in solid tumor, pancreatic cancer (PC), breast cancer and 5 more (6 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants with Dose Limited Toxicity at 28 days and Objective Response Rate at 5 years. Started Oct 2025; status: recruiting.
02
Drugs
PNT6555
03
Conditions
solid tumorpancreatic cancer (PC)breast cancerovarian cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT07213791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213791.